Cargando…

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection

Detalles Bibliográficos
Autores principales: Chow, Shien, Evans, Manon, Galvis, Victoria, Leach, Rebecca, Keene, Elizabeth, Chan, Kevin, Spencer-Shaw, Andrea, Jonathan, Shanks, Shabalak, Alaaeldin, Thistlethwaite, Fiona, Hawkins, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/
http://dx.doi.org/10.1186/2051-1426-2-S3-P89
_version_ 1782352020571684864
author Chow, Shien
Evans, Manon
Galvis, Victoria
Leach, Rebecca
Keene, Elizabeth
Chan, Kevin
Spencer-Shaw, Andrea
Jonathan, Shanks
Shabalak, Alaaeldin
Thistlethwaite, Fiona
Hawkins, Robert
author_facet Chow, Shien
Evans, Manon
Galvis, Victoria
Leach, Rebecca
Keene, Elizabeth
Chan, Kevin
Spencer-Shaw, Andrea
Jonathan, Shanks
Shabalak, Alaaeldin
Thistlethwaite, Fiona
Hawkins, Robert
author_sort Chow, Shien
collection PubMed
description
format Online
Article
Text
id pubmed-4288767
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42887672015-01-15 High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection Chow, Shien Evans, Manon Galvis, Victoria Leach, Rebecca Keene, Elizabeth Chan, Kevin Spencer-Shaw, Andrea Jonathan, Shanks Shabalak, Alaaeldin Thistlethwaite, Fiona Hawkins, Robert J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288767/ http://dx.doi.org/10.1186/2051-1426-2-S3-P89 Text en Copyright © 2014 Chow et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Chow, Shien
Evans, Manon
Galvis, Victoria
Leach, Rebecca
Keene, Elizabeth
Chan, Kevin
Spencer-Shaw, Andrea
Jonathan, Shanks
Shabalak, Alaaeldin
Thistlethwaite, Fiona
Hawkins, Robert
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title_full High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title_fullStr High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title_full_unstemmed High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title_short High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
title_sort high-dose interleukin-2 (hd-il2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/
http://dx.doi.org/10.1186/2051-1426-2-S3-P89
work_keys_str_mv AT chowshien highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT evansmanon highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT galvisvictoria highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT leachrebecca highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT keeneelizabeth highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT chankevin highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT spencershawandrea highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT jonathanshanks highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT shabalakalaaeldin highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT thistlethwaitefiona highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection
AT hawkinsrobert highdoseinterleukin2hdil2intreatmentnaivemetastaticrenalcellcarcinomamrcca10yearsinglesiteexperienceandoutcomeofprospectivepathologybasedpatientselection